World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
99
Citations
39869
World Ranking
8532
National Ranking
16

Chong-Jen Yu publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Chong-Jen Yu sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 726 publications — 83rd percentile

83% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Chong-Jen Yu D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Chong-Jen Yu sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 99 D-Index — 58th percentile

58% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Chong-Jen Yu is affiliated with National Taiwan University in Taiwan, focusing primarily on medical research. Their work spans several interconnected fields within medicine, including pulmonary and respiratory medicine, oncology, infectious diseases, epidemiology, and surgery.

The scientist's research topics cover a variety of areas related to lung health and cancer, as well as infectious diseases and chronic conditions. Key topics include:

  • Lung Cancer Treatments and Mutations
  • Lung Cancer Diagnosis and Treatment
  • Tuberculosis Research and Epidemiology
  • Lung Cancer Research Studies
  • Mycobacterium Research and Diagnosis
  • Chronic Obstructive Pulmonary Disease (COPD) Research
  • Cancer Immunotherapy and Biomarkers

Chong-Jen Yu has contributed extensively to the medical literature, with 448 publications categorized under medicine. Within that body of work, subfields with significant contributions include pulmonary and respiratory medicine (172 publications), oncology (64 publications), infectious diseases (49 publications), epidemiology (45 publications), and surgery (27 publications).

Frequent publication venues for the scientist include:

  • Annals of Oncology
  • Journal of Thoracic Oncology
  • Journal of the Formosan Medical Association
  • SLEEP
  • Journal of Microbiology Immunology and Infection

Among recent papers, notable examples are:

  • Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer (2020), published in New England Journal of Medicine
  • Renal Involvement and Early Prognosis in Patients with COVID-19 Pneumonia (2020), published in Journal of the American Society of Nephrology
  • Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non-Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial (2023), published in Journal of Clinical Oncology
  • Risk Factors for Mortality in 244 Older Adults With COVID-19 in Wuhan, China: A Retrospective Study (2020), published in Journal of the American Geriatrics Society
  • Nivolumab with carboplatin, paclitaxel, and bevacizumab for first-line treatment of advanced nonsquamous non-small-cell lung cancer (2021), published in Annals of Oncology

Frequent co-authors collaborating with Chong-Jen Yu include:

  • Jin-Yuan Shih
  • Jung-Yien Chien
  • Hao-Chien Wang
  • Chao-Chi Ho
  • Jann-Yuan Wang

Best Publications

  • MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib

    James Bean;Cameron Brennan;Jin-Yuan Shih;Gregory Riely

  • Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer.

    Yi-Long Wu;Masahiro Tsuboi;Jie He;Thomas John

  • First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study

    Jean-Charles Soria;Daniel S W Tan;Rita Chiari;Yi-Long Wu

  • Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6.

    James C.H. Yang;Lecia V. Sequist;Sarayut Lucien Geater;Chun Ming Tsai

  • MicroRNA Signature Predicts Survival and Relapse in Lung Cancer

    Sung Liang Yu;Hsuan Yu Chen;Hsuan Yu Chen;Gee Chen Chang;Chih Yi Chen

  • Value of sonography in determining the nature of pleural effusion: analysis of 320 cases.

    Pan-Chyr Yang;Kwen-Tay Luh;Dun-Bing Chang;Huey-Dong Wu

  • Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy

    Tony S.K. Mok;Yi-Long Wu;Jin Soo Lee;Chong-Jen Yu

  • Mycobacterium abscessus Complex Infections in Humans.

    Meng-Rui Lee;Wang-Huei Sheng;Chien-Ching Hung;Chong-Jen Yu

  • Effectiveness of Tyrosine Kinase Inhibitors on “Uncommon” Epidermal Growth Factor Receptor Mutations of Unknown Clinical Significance in Non–Small Cell Lung Cancer

    Jenn-Yu Wu;Chong-Jen Yu;Yeun-Chung Chang;Chih-Hsin Yang

  • Low serum level of high-density lipoprotein cholesterol is a poor prognostic factor for severe sepsis.

    Jung-Yien Chien;Jih-Shuin Jerng;Chong-Jen Yu;Pan-Chyr Yang

  • Sialylation and fucosylation of epidermal growth factor receptor suppress its dimerization and activation in lung cancer cells

    Ying-Chih Liu;Hsin-Yung Yen;Chien-Yu Chen;Chein-Hung Chen

  • Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial

    Yi Long Wu;Jin Soo Lee;Sumitra Thongprasert;Chong Jen Yu

  • Pulmonary Sequelae in Convalescent Patients after Severe Acute Respiratory Syndrome: Evaluation with Thin-Section CT

    Yeun-Chung Chang;Chong-Jen Yu;Shan-Chwen Chang;Jeffrey R Galvin

  • Lung cancer with epidermal growth factor receptor exon 20 mutations is associated with poor gefitinib treatment response.

    Jenn-Yu Wu;Shang-Gin Wu;Chih-Hsin Yang;Chien-Hung Gow

  • Genome-wide association analysis identifies new lung cancer susceptibility loci in never-smoking women in Asia.

    Qing Lan;Chao A. Hsiung;Keitaro Matsuo;Yun Chul Hong

  • Specific EGFR Mutations Predict Treatment Outcome of Stage IIIB/IV Patients With Chemotherapy-Naive Non–Small-Cell Lung Cancer Receiving First-Line Gefitinib Monotherapy

    Chih-Hsin Yang;Chong-Jen Yu;Jin-Yuan Shih;Yeun-Chung Chang

  • Vascular Endothelial Growth Factor 189 mRNA Isoform Expression Specifically Correlates With Tumor Angiogenesis, Patient Survival, and Postoperative Relapse in Non–Small-Cell Lung Cancer

    Ang Yuan;Chong-Jen Yu;Sow-Hsong Kuo;Wen-Jone Chen

  • Transcription repressor slug promotes carcinoma invasion and predicts outcome of patients with lung adenocarcinoma.

    Jin Yuan Shih;Meng Feng Tsai;Tzu Hua Chang;Yih Leong Chang

  • Comparison of epidermal growth factor receptor mutations between primary and corresponding metastatic tumors in tyrosine kinase inhibitor-naive non-small-cell lung cancer

    C.-H. Gow;Y.-L. Chang;Y.-C. Hsu;M.-F. Tsai

  • Temporal changes in cytokine/chemokine profiles and pulmonary involvement in severe acute respiratory syndrome.

    Jung-Yien Chien;Po-Ren Hsueh;Wern-Cherng Cheng;Chong-Jen Yu

Frequent Co-Authors

Pan-Chyr Yang
Pan-Chyr Yang National Taiwan University
Po-Ren Hsueh
Po-Ren Hsueh China Medical University
Kwen-Tay Luh
Kwen-Tay Luh National Taiwan University
James Chih-Hsin Yang
James Chih-Hsin Yang National Taiwan University
Yi-Long Wu
Yi-Long Wu Guangdong Provincial People’s Hospital
Wu Chou Su
Wu Chou Su National Cheng Kung University
Tony Mok
Tony Mok Chinese University of Hong Kong
Jianjun Liu
Jianjun Liu Genome Institute of Singapore
Meredith Yeager
Meredith Yeager Hood College
Chien-Jen Chen
Chien-Jen Chen Academia Sinica

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Pursuing a career in medicine doesn’t always mean becoming a doctor. The healthcare industry offers a range of educational pathways, including flexible online options that cater to different interests and backgrounds.

For those interested in nursing, you can find the easiest bsn program to get into or consider a nursing school that don't require teas, making admission more accessible to a wider range of applicants. These routes let students begin their nursing careers faster and with less stress during the application process.

If you prefer administrative or non-clinical roles, consider enrolling in one of the best medical billing and coding schools online. These programs prepare you for vital roles in healthcare administration, where demand continues to grow.

Aspiring healthcare leaders may also explore online health administration programs for accelerated degrees. This pathway is ideal if you want to impact patient care at a systems level, manage teams, and oversee hospital operations.

Best Scientists Citing Chong-Jen Yu

Trending Scientists

Recently Published Articles